September 27, 2022

THE MINISTRY FOR INCLUSION, VOLUNTARY ORGANISATIONS AND CONSUMER RIGHTS AND THE MINISTRY FOR THE ENVIRONMENT, ENERGY AND ENTERPRISE Sustainable Development Fund for voluntary organisations

Voluntary organisations have the opportunity to apply for a scheme issued by the Sustainable Development Directorate and the Malta Council for the Voluntary Sector. This scheme includes an investment of €50,000 in order to assist organisations to implement tangible projects or initiatives related to the promotion of sustainable development. This was announced during the European Sustainable Development Week by Minister for the Environment, Energy and Enterprise, Miriam Dalli together with Minister for Inclusion, Voluntary Organisations and Consumer Rights Julia Farrugia Portelli. Minister Miriam Dalli explained that the main objective of this fund is to assist voluntary organisations improve their capacity

CONTINUE READING

As Ebola Spreads, Ugandan Medical Interns Strike Over Safety

As Uganda reports more deaths from the latest Ebola outbreak in the country, medical interns at the hospital handling most of the cases have gone on strike. The interns say they are not being provided with adequate personal protective equipment against the deadly virus, which causes a hemorrhagic fever. Uganda’s health ministry has so far confirmed five deaths and 18 probable fatalities out of 36 cases. Ugandan Health officials say they are holding talks with striking interns at central Mubende district’s hospital, which is handling most of the country’s spreading Ebola outbreak. President for the Federation for Uganda Medical Interns,

CONTINUE READING

Experimental Alzheimer’s Drug Said to Succeed in Slowing Cognitive Decline

An experimental Alzheimer’s drug developed by Eisai and Biogen significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said Tuesday. The injected drug, lecanemab, slowed progress of the brain-wasting disease by 27% compared with a placebo, meeting the study’s main goal and offering an apparent win for the companies and potentially for patients and their families desperate for an effective treatment. Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of

CONTINUE READING